AZN - Altimmune: The Late Bloomer Of The COVID-19 Biotech World The Best Is Yet To Come
Source: Altimmune Website
Company Background:
Altimmune (ALT) is a US biopharmaceutical company based in Gaithersburg, Maryland, USA, which focuses on developing treatments for liver disease, immune-modulating therapies, and vaccines. Altimmune has various pre-clinical to clinical pipeline candidates for NASH (ALT-801), chronic hepatitis B (HepTcell), cancer (ALT-702), and intranasal vaccines (NasoVAX and NasoShield). I am particularly interested in ALT's COVID-19 programs because it is the most important short-term driver for ALT's stock price. I believe its NASH and chronic hepatitis B initiative will emerge as encouraging assets in the long term. The promising outlook